GlaxoSmithKline HIF-PH inhibitors have been approved in Japan.

On June 29, GSK announced that its oral reactive hypooxyely induced factor promatose hydroxylase inhibitor (HIF-PHI) Duvroq (daprodustat) was approved for the treatment of chronic kidney disease anemia in Japan.
nephrotic anemia is one of the most common complications of chronic kidney disease (CKD), and it is estimated that there are about 1090 cases of CKD at level 3-5 in Japan, of which 32% suffer from anemia.
poor control of nephronomic anemia will increase the risk of cardiovascular events and death in dialysis patients, not only affecting their physical and mental health and social function, but also putting a heavy burden on their families and society.
2017, the number of people affected by CKD worldwide accounts for about one-tenth of the world's total, resulting in more than 1 million deaths.
HIF-PHI is a new type of drug, hIF physiological action can not only increase the expression of erythropoietin, but also red blood cell receptorand and promote iron absorption and circulation protein expression.
the results have been awarded the 2019 Nobel Prize in Physiology or Medicine.
the world's first approved HIF-PHI drug is AstraZeneca's Rosasta, which was approved in Japan in September 2019.
GSK's Duvroq has not yet been approved in Europe and the United States, and Duvroq's distribution in Japan is the responsibility of Concord Fermentation Kirin.
Phase III clinical trials conducted in Japan have shown that Duvroq's higher standard therapy provides dialysis and non-dialysis patients with the convenience and flexibility of 1 oral oral time per day, regardless of whether the patient has previously been treated with erythrometic irritants (ESA).
.